- Home
- FGNX vs IXHL Comparison
FGNX vs IXHL Comparison
Compare FGNX & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | FGNX | IXHL |
|---|---|---|
| Founded | 1932 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 127.4M | 134.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FGNX | IXHL |
|---|---|---|
| Price | $3.01 | $0.36 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | 557.1K | ★ 7.5M |
| Earning Date | 02-19-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $17,450,000.00 | $12,000.00 |
| Revenue This Year | $95.83 | N/A |
| Revenue Next Year | $42.41 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 144.71 | N/A |
| 52 Week Low | $2.30 | $0.08 |
| 52 Week High | $41.25 | $2.25 |
Technical Indicators
Market Signals| Indicator | FGNX | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 40.72 |
| Support Level | N/A | $0.34 |
| Resistance Level | N/A | $0.42 |
| Average True Range (ATR) | 0.00 | 0.02 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 0.00 | 21.16 |
Price Performance
Historical ComparisonAbout FGNX Fundamental Global Inc.
FG Nexus Inc is a capital markets platform focused on long-term Ethereum (ETH) accumulation and on-chain yield generation. The company provides institutional investors with secure, regulated access to ETH as a productive reserve asset, generating native staking yield while underpinning stablecoins, tokenized assets, and AI-driven applications.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.